Report of an additional case of anti-tumor necrosis factor therapy and Listeria monocytogenes infection: comment on the letter by Glück et al.
Aparicio
Angel Garcia
AG
Muñoz-Fernández
Santiago
S
Bonilla
Gema
G
Miralles
Ambrosio
A
Cerdeño
Victor
V
Martín-Mola
Emilio
E
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology*; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000276:immunology; D015535:Arthritis, Psoriatic / Q000150:complications / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000276:immunology; D007213:Indomethacin / Q000627:therapeutic use; D000069285:Infliximab; D008089:Listeria monocytogenes / Q000302:isolation & purification* / Q000472:pathogenicity; D008088:Listeriosis / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D011239:Prednisolone; D000069285:Infliximab; D007213:Indomethacin